|Venture Round, 6/2010 |
Sparbankstiftelsen SkÃ¥nes Riskkapitalstiftels
Adenovir Pharma AB is a development company developing new solutions for treatment of infectious diseases affecting the eyes.
Adenovir Pharma was founded by researchers at the department of Virology, UmeÃ¥ University, Sweden and P.U.L.S. AB which acts as an incubator and financer for early stage projects within life science. Adenovir Pharma is located in Helsingborg Sweden in one of Europeâ€™s premier biotechnology regions, Medicon Valley. The initial development has been conducted at the University of Lund, Department of Organic Chemistry and at the University of UmeÃ¥, Department of Virology and in collaboration with P.U.L.S. AB and external service providers.
With unique patented technology and own product concepts, Adenovir Pharma aim to offer new treatments and business development opportunities to the pharmaceutical industry. The goal is to develop a new antiviral medicinal product for the treatment and prevention of epidemic keratoconjunctivities (EKC).